
Lonza

Amaxa[®] Cell Line Nucleofector[®] Kit R


For NIH/3T3 (ATCC[®] CRL-1658[™])

NIH Swiss mouse embryo; adherent fibroblastoid cells

Example for Nucleofection[®] of NIH/3T3 (ATCC[®] CRL-1658[™])



NIH/3T3 cells (ATCC[®] CRL-1658[™]) were transfected with the Nucleofector[®] Kit R, Program U-030 and a plasmid encoding the enhanced green fluorescent protein eGFP. 5 hours post Nucleofection[®], the cells were analyzed by light (A) and fluorescence microscopy (B).



Average transfection efficiency of NIH/3T3 cells. NIH/3T3 cells (ATCC° CRL-1658") were transfected with program U-030 and 3 μg of plasmid encoding the enhanced green fluorescent protein eGFP. 5 and 24 hours post Nucleofection®, the cells were analyzed by flow cytometry.

Product Description

Cat. No.		VCA-1001
Size (reactions)		25
Cell Line Nucleofector [®] Solution R		2.25 ml (2.05 ml + 10% overfill)
Supplement		0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 µg/µl in 10 mM Tris pH 8.0)		30 µg
Certified cuvettes		25
Plastic pipettes		25
Storage and stability	Store Nucleofector® So	lution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage,
	pmaxGFP® Vector is idea	Ily stored at -20°C. The expiration date is printed on the solution box. Once the
	Nucleofector [®] Suppleme	ent is added to the Nucleofector [®] Solution it is stable for three months at 4°C.

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5 : 1. For a single reaction use 82 µl of Nucleofector® Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector[®] Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP[®] Vector
- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260: A280 ratio should be at least 1.8
- 6-well culture dish or culture system of your choice
- For detaching cells: 0.5 mg/ml Trypsin and 0.2 mg/ml EDTA in PBS
- Culture medium: 90% Dulbecco's modified Eagle medium (DMEM) with 4 mM Lglutamine, 1.5 g/l sodium bicarbonate and 4.5 g/l glucose [ATCC[®], Cat; No. 30-2002] and 10% Bovine Calf Serum [ATCC[®]; Cat. No. 30-2030]. The medium and the FBS have a tremendous influence on both the transfection efficiency and cell survival of this cell line. We strongly recommend to use medium and FBS from ATCC[®] for culture and Nucleofection[®] Experiments
- Prewarm appropriate volume of culture medium to 37°C (1.5 ml per sample)
- Appropriate number of cells (1 x 10⁶ cells per sample ; lower or higher cell numbers may influence transfection results)

1. Pre Nucleofection®

Cell culture recommendations

- 1.1 Replace media every 2 days
- 1.2 Passage cells at 70 80 % confluency. The cell layer should not become completely confluent
- 1.3 Seed out $10^2-10^3\,cells/cm^2$
- 1.4 Cells should be passaged 2 3 days before Nucleofection $^{\circledast}$
- 1.5 Optimal confluency for Nucleofection[®]: 80 90%. Higher cell densities may cause lower Nucleofection[®] Efficiencies

Trypsinization

- 1.6 Remove media from the cultured cells and wash cells once with PBS
- 1.7 Harvest the cells, e.g. with trypsin/EDTA and stop the trypsinization with supplemented culture medium or PBS/0.5% BSA
- 1.8 Take an aliquot of trypsinized cell suspension and count the cells to determine the cell density

2. Nucleofection®

One Nucleofection® Sample contains

1 x 10⁶ cells

 $1-5 \mu g$ plasmid DNA (in $1-2 \mu l H_2 0$ or TE) or $2 \mu g$ pmaxGFP[®] Vector or 30-300 n M siRNA

(0.6 – 6 pmol/sample)

100 µl Cell Line Nucleofector® Solution R

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 6-well plates by filling appropriate number of wells with 1 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.3 Harvest the cells by trypsinization (please see 1.7 1.8)
- 2.4 Count an aliquot of the cells and determine cell density
- 2.5 Centrifuge the required number of cells (1 x 10⁶ cells per sample) at 200xg for 10 minutes at room temperature. Remove supernatant completely
- 2.6 Resuspend the cell pellet carefully in 100 µl room-temperature Nucleofector® Solution per sample

Note Avoid leaving the cells in Nucleofector[®] Solution for extended periods of time (longer than 15 minutes), as this may reduce cell viability.

- 2.7 Combine 100 μ l of cell suspension with 1 5 μ g DNA, 2 μ g pmaxGFP® Vector or appropriate amount of siRNA (30 nM 300 nM or 0.6 6 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.9 Select the appropriate Nucleofector® Program U-030 (U-30 for Nucleofector® | Device)
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector[®] Cuvette Holder and apply the selected program by pressing the X-button
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Immediately add ~500 µl of the pre-equilibrated culture medium to the cuvette and gently transfer the sample into the prepared 6-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection®

3.1 Incubate the cells in humidified 37°C/5% CO_2 incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4 – 8 hours

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA/Canada Phone: 800 521 0390 (toll-free) Fax: 301 845 8338 E-mail: scientific.support@lonza.com Europe and Rest of World Phone: +49 221 99199 400 Fax: +49 221 99199 499 E-mail: scientific.support.eu@lonza.com

References

1. Martinez-Gonzalez J et al., Circ Res. 2003;92(1):96-103

Lonza Cologne AG 50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are either registered trademarks or trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

 $\text{ATCC}^{\circledast}$ and the $\text{ATCC}^{\circledast}$ Catalog Marks are trademarks of $\text{ATCC}^{\circledast}.$

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne AG. All rights reserved DCR-1003 05/09